Yüklüyor......
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope(®) (biosimilar rhGH) was approved by the European Medicines Agency in 2006, with approval granted...
Kaydedildi:
| Yayımlandı: | Drug Des Devel Ther |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5439985/ https://ncbi.nlm.nih.gov/pubmed/28553080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S130909 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|